Mutation of NRAS (particularly in codon Q61) occurs in around 15–20% of melanomas, with NRAS being considered an ‘undruggable target’, and thus an attractive candidate for synthetic lethal screening (Hodis et al., 2012). This evidence concerns the gene NRAS and melanoma.